Geron Corp (GERN) and General Electric Co unit GE Healthcare said they agreed to develop and market embryonic stem cell products for use in drug discovery, development and toxicity screening.
The companies said the program will use stem cells derived from human embryonic stem cell lines listed on the National Institutes of Health’s Human Pluripotent Stem Cell Registry, but did not disclose the financial terms of the deal.
The first products developed in the alliance are expected to be available by early 2010, with a pipeline of products to follow, the companies said. Stock Market Newz has more.
Market Club has a very interesting take on how GERN is playing out after the past volume surge. The “Trade Triangles” paint the picture. CLICK HERE and just enter the ticker (GERN) your name and e-mail address for the FREE No strings Attached Report sent realtime to your in-box!
FREE Trend Analysis for GERN Here
“This will be the first real economic application of stem cells,” said Konstantin Fiedler, general manager of cell technologies at GE Healthcare. “We’ll not be the only one out there but we’re very confident we will be one of the main players. We see a significant market opportunity.”
